Literature DB >> 28391502

Genomic analysis of chimeric human cytomegalovirus vaccine candidates derived from strains Towne and Toledo.

Nicolás M Suárez1, Betty Lau1, George M Kemble2, Ronzo Lee3, Edward S Mocarski4, Gavin W G Wilkinson5, Stuart P Adler6, Michael A McVoy7, Andrew J Davison1.   

Abstract

Human cytomegalovirus (HCMV) is an important opportunistic pathogen in immunocompromised patients and a major cause of congenital birth defects when acquired in utero. In the 1990s, four chimeric viruses were constructed by replacing genome segments of the high passage Towne strain with segments of the low passage Toledo strain, with the goal of obtaining live attenuated vaccine candidates that remained safe but were more immunogenic than the overly attenuated Towne vaccine. The chimeras were found to be safe when administered to HCMV-seronegative human volunteers, but to differ significantly in their ability to induce seroconversion. This suggests that chimera-specific genetic differences impacted the ability to replicate or persist in vivo and the consequent ability to induce an antibody response. To identify specific genomic breakpoints between Towne and Toledo sequences and establish whether spontaneous mutations or rearrangements had occurred during construction of the chimeras, complete genome sequences were determined. No major deletions or rearrangements were observed, although a number of unanticipated mutations were identified. However, no clear association emerged between the genetic content of the chimeras and the reported levels of vaccine-induced HCMV-specific humoral or cellular immune responses, suggesting that multiple genetic determinants are likely to impact immunogenicity. In addition to revealing the genome organization of the four vaccine candidates, this study provided an opportunity to probe the genetics of HCMV attenuation in humans. The results may be valuable in the future design of safe live or replication-defective vaccines that optimize immunogenicity and efficacy.

Entities:  

Keywords:  Attenuation; Cytomegalovirus; Recombinant; Vaccine; Virulence

Mesh:

Substances:

Year:  2017        PMID: 28391502      PMCID: PMC5527331          DOI: 10.1007/s11262-017-1452-0

Source DB:  PubMed          Journal:  Virus Genes        ISSN: 0920-8569            Impact factor:   2.332


  37 in total

1.  Peptides from cytomegalovirus UL130 and UL131 proteins induce high titer antibodies that block viral entry into mucosal epithelial cells.

Authors:  Frances M Saccoccio; Anne L Sauer; Xiaohong Cui; Amy E Armstrong; El-Sayed E Habib; David C Johnson; Brent J Ryckman; Aloysius J Klingelhutz; Stuart P Adler; Michael A McVoy
Journal:  Vaccine       Date:  2011-02-22       Impact factor: 3.641

2.  Dendritic-cell infection by human cytomegalovirus is restricted to strains carrying functional UL131-128 genes and mediates efficient viral antigen presentation to CD8+ T cells.

Authors:  Giuseppe Gerna; Elena Percivalle; Daniele Lilleri; Laura Lozza; Chiara Fornara; Gabriele Hahn; Fausto Baldanti; M Grazia Revello
Journal:  J Gen Virol       Date:  2005-02       Impact factor: 3.891

3.  Human cytomegalovirus UL131 open reading frame is required for epithelial cell tropism.

Authors:  Dai Wang; Thomas Shenk
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

4.  A phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines.

Authors:  Thomas C Heineman; Mark Schleiss; David I Bernstein; Richard R Spaete; Lihan Yan; Greg Duke; Mark Prichard; Zhaoti Wang; Qing Yan; Margaret A Sharp; Nicola Klein; Ann M Arvin; George Kemble
Journal:  J Infect Dis       Date:  2006-04-12       Impact factor: 5.226

5.  Antibodies against neutralization epitopes of human cytomegalovirus gH/gL/pUL128-130-131 complex and virus spreading may correlate with virus control in vivo.

Authors:  Daniele Lilleri; Anna Kabanova; Antonio Lanzavecchia; Giuseppe Gerna
Journal:  J Clin Immunol       Date:  2012-07-27       Impact factor: 8.317

6.  Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection.

Authors:  Xiaohong Cui; Benjamin P Meza; Stuart P Adler; Michael A McVoy
Journal:  Vaccine       Date:  2008-08-19       Impact factor: 3.641

7.  Reconstruction of the complete human cytomegalovirus genome in a BAC reveals RL13 to be a potent inhibitor of replication.

Authors:  Richard J Stanton; Katarina Baluchova; Derrick J Dargan; Charles Cunningham; Orla Sheehy; Sepehr Seirafian; Brian P McSharry; M Lynne Neale; James A Davies; Peter Tomasec; Andrew J Davison; Gavin W G Wilkinson
Journal:  J Clin Invest       Date:  2010-08-02       Impact factor: 14.808

8.  High-throughput sequence analysis of variants of human cytomegalovirus strains Towne and AD169.

Authors:  Amanda J Bradley; Nell S Lurain; Peter Ghazal; Urmi Trivedi; Charles Cunningham; Katarina Baluchova; Derek Gatherer; Gavin W G Wilkinson; Derrick J Dargan; Andrew J Davison
Journal:  J Gen Virol       Date:  2009-06-24       Impact factor: 3.891

Review 9.  Human cytomegalovirus: taking the strain.

Authors:  Gavin W G Wilkinson; Andrew J Davison; Peter Tomasec; Ceri A Fielding; Rebecca Aicheler; Isa Murrell; Sepher Seirafian; Edward C Y Wang; Michael Weekes; Paul J Lehner; Gavin S Wilkie; Richard J Stanton
Journal:  Med Microbiol Immunol       Date:  2015-04-17       Impact factor: 4.148

10.  First fatality associated with elephant endotheliotropic herpesvirus 5 in an Asian elephant: pathological findings and complete viral genome sequence.

Authors:  Gavin S Wilkie; Andrew J Davison; Karen Kerr; Mark F Stidworthy; Sharon Redrobe; Falko Steinbach; Akbar Dastjerdi; Daniela Denk
Journal:  Sci Rep       Date:  2014-09-09       Impact factor: 4.379

View more
  8 in total

Review 1.  Progress toward Development of a Vaccine against Congenital Cytomegalovirus Infection.

Authors:  Mark R Schleiss; Sallie R Permar; Stanley A Plotkin
Journal:  Clin Vaccine Immunol       Date:  2017-12-05

Review 2.  Vaccine vectors: the bright side of cytomegalovirus.

Authors:  Andrea C Méndez; Cristina Rodríguez-Rojas; Margarita Del Val
Journal:  Med Microbiol Immunol       Date:  2019-03-21       Impact factor: 3.402

Review 3.  A fifty-year odyssey: prospects for a cytomegalovirus vaccine in transplant and congenital infection.

Authors:  Don Jeffrey Diamond; Corinna La Rosa; Flavia Chiuppesi; Heidi Contreras; Sanjeet Dadwal; Felix Wussow; Supriya Bautista; Ryotaro Nakamura; John A Zaia
Journal:  Expert Rev Vaccines       Date:  2018-10-03       Impact factor: 5.217

Review 4.  HLA-E: exploiting pathogen-host interactions for vaccine development.

Authors:  H R Sharpe; G Bowyer; S Brackenridge; T Lambe
Journal:  Clin Exp Immunol       Date:  2019-04-09       Impact factor: 4.330

5.  Inclusion of the Guinea Pig Cytomegalovirus Pentameric Complex in a Live Virus Vaccine Aids Efficacy against Congenital Infection but Is Not Essential for Improving Maternal and Neonatal Outcomes.

Authors:  Mark R Schleiss; Claudia Fernández-Alarcón; Nelmary Hernandez-Alvarado; Jian Ben Wang; Adam P Geballe; Michael A McVoy
Journal:  Viruses       Date:  2021-11-26       Impact factor: 5.818

6.  Fibroblast-adapted human CMV vaccines elicit predominantly conventional CD8 T cell responses in humans.

Authors:  Susan E Murray; Pavlo A Nesterenko; Adam L Vanarsdall; Michael W Munks; Savannah M Smart; Eren M Veziroglu; Lavinia C Sagario; Ronzo Lee; Frans H J Claas; Ilias I N Doxiadis; Michael A McVoy; Stuart P Adler; Ann B Hill
Journal:  J Exp Med       Date:  2017-05-31       Impact factor: 14.307

7.  Advances in the treatment of cytomegalovirus.

Authors:  B A Krishna; M R Wills; J H Sinclair
Journal:  Br Med Bull       Date:  2019-09-19       Impact factor: 4.291

8.  Human Cytomegalovirus RNA2.7 Is Required for Upregulating Multiple Cellular Genes To Promote Cell Motility and Viral Spread Late in Lytic Infection.

Authors:  Betty Lau; Karen Kerr; Salvatore Camiolo; Katie Nightingale; Quan Gu; Robin Antrobus; Nicolás M Suárez; Colin Loney; Richard J Stanton; Michael P Weekes; Andrew J Davison
Journal:  J Virol       Date:  2021-08-04       Impact factor: 6.549

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.